Cuba rolls out two COVID-19 vaccines still in trial phase | Inquirer News

Cuba rolls out two COVID-19 vaccines still in trial phase

/ 11:22 AM May 13, 2021

In this file photo taken on March 31, 2021, nurse Xiomara Rodriguez shows a vial of the Cuban Soberana 2 vaccine candidate to be administered to a volunteer during its trial Phase III in Havana. Cuba will begin immunizing its population against the coronavirus during the first half of May, mainly in Havana and the provinces of Santiago de Cuba (east) and Matanzas (center), with two vaccine candidates developed on the island, officials said on May 7, 2021. Photo by Joaquin Hernandez / AFP

HAVANA — Faced with a surge in coronavirus cases, Cuba this week started immunizing members of the public, using two locally-produced vaccines that have yet to complete clinical trials.

The island nation of 11.2 million inhabitants recorded 1,207 new daily cases on Wednesday — a near record for Cuba — as inhabitants of Havana and other provinces received their first dose of Abdala, one of two candidate shots in Phase II trials.


“A slight sensation of warmth during the injection” but “all is well,” Cecilia Reyes, 69, one of the first Abdala recipients, said of the experience.

The rollout began with the blessing of the health ministry as authorities eye official approval of the Abdala and Soberana 2 vaccines by Cuba’s drug authority by June.


The communist state, which has stated it wants to vaccinate all inhabitants this year, has been relatively unscathed by the Covid-19 pandemic, with over 119,000 reported cases and 768 deaths to date.

Under American sanctions, Cuba has a long tradition of making its own vaccines, dating back to the 1980s.

Nearly 80 percent of its vaccines are produced locally, and Cuba is working on five coronavirus candidate vaccines. If one of them gets the green light, it will be the first coronavirus vaccine developed in Latin America.

Cuba has not bought or sought coronavirus vaccines from elsewhere.

In March, the country started vaccinating health care workers with Abdala and Soberana 2.

Abdala has completed its Phase III trial, but the results are still being analyzed. Soberana 2 is due to complete the final trial phase within days.

Phase II results, the authorities say, showed positive results in terms of efficacy and safety.


Initially, the government had planned to roll out its vaccine program to the public in June, after authorization.

“If it were not for this epidemical situation, (the authorities) would have waited longer,” said molecular biologist and researcher Amilcar Perez-Riverol of the Sao Paulo University, referring to the new infection surge.

Health Minister Jose Angel Portal said between 1.7 million of the 2.1 million inhabitants of Havana, the epicenter of the outbreak, will be vaccinated between now and August.

Of the island’s total population, 22.6 percent should have received both shots by June, 33.5 percent by July, and 70 percent by August, he said.

Any criticism of Cuba’s decision to jump the gun will become moot if the trial results come back positive, said Perez-Riverol, pointing to Russia and China which had also put home-made vaccines to use before trials were completed.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: COVID-19, Cuba
For feedback, complaints, or inquiries, contact us.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.

© Copyright 1997-2022 | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.